410527-75-2
Chemical Structure
TET 830 modified/T-helper epitope from tetanus toxoid
- CAS No.: 410527-75-2
- Formula:C83H134N20O24
- Molecular Weight:1796.07
SMILES: OC(C=C1)=CC=C1C[C@H](NC([C@H](CCC(N)=O)NC([C@@H](N)C)=O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)=O)=O
Biological Activity: TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope peptide and an HLA-DR/MHC class II-restricted tetanus helper epitope. TET 830 modified/T-helper epitope from tetanus toxoid is used in the research of melanoma and ovarian cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TET 830 modified/T-helper epitope from tetanus toxoid | 99.91% | TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope peptide and an HLA-DR/MHC class II-restricted tetanus helper epitope. TET 830 modified/T-helper epitope from tetanus toxoid is used in the research of melanoma and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Slingluff CL Jr, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24. [Content Brief]
- [2]. Slingluff CL, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Nov 15;22(22):4474-85.
- [3]. Chianese-Bullock KA, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008 May;31(4):420-30.
